Q1FY27 saw a revenue decline due to timing shifts in deliveries, but margins improved year-over-year, with EBITDA margin rising to 39.6% and PAT margin to 27.1%. Strong net cash and robust demand position the company for a stronger second half.Original document: Anthem Biosciences Limited [ANTHEM…
Q1FY27 saw a revenue decline due to timing shifts in deliveries, but margins improved year-over-year, with EBITDA margin rising to 39.6% and PAT margin to 27.1%. Strong net cash and robust demand position the company for a stronger second half.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.